News | Defibrillator Monitors | July 28, 2023

GE HealthCare Recalls TruSignal SpO2 Sensors for Issues That May Reduce Defibrillation Energy, Expose Patients to Unintended Voltage, or Give Inaccurate Readings

GE HealthCare is recalling malfunctioning TruSignal sensors that may reduce the amount of energy sent to the heart during defibrillation without any notification to the care provider

GE HealthCare is recalling malfunctioning TruSignal sensors that may reduce the amount of energy sent to the heart during defibrillation without any notification to the care provider

July 28, 2023 — GE HealthCare is recalling malfunctioning TruSignal sensors that may reduce the amount of energy sent to the heart during defibrillation without any notification to the care provider, which could prevent delivery of lifesaving therapy in a critical situation. This issue is most hazardous to hospitalized patients who may need defibrillation for cardiac arrest. Affected sensors may also unintentionally expose patients to electrical currents from other sources or may provide inaccurate measurements of SpO2, which can impact treatment decisions.  

The U.S. Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries, serious health consequences, or death. 

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. 

Recalled Product  

Product Names:  

  • TruSignal Adult Pediatric Sensor  
  • TruSignal AllFit Sensor  
  • TruSignal Sensitive Skin Sensor  
  • TruSignal Wrap Sensor 
  • TruSignal Ear Sensor  
  • TruSignal Integrated Ear Sensor with GE Connector  
  • TruSignal Integrated Ear Sensor with Datex Connector  
  • TruSignal Integrated Ear Sensor with Datex Connector  
  • TruSignal Integrated Ear Sensor with Ohmeda Connector  

Distribution Dates: January 1, 2021 to March 4, 2023 

Devices Recalled in the U.S.: 7,559 

Date Initiated by Firm: May 19, 2023 

Device Use 

TruSignal sensors continuously monitor the amount of oxygen found in the blood flowing through the arteries (arterial oxygen saturation or SpO2) and pulse rate through a sensor placed on the skin. The sensors are designed and tested to help ensure patients have enough oxygen in their blood to keep their bodies functioning and to give care providers information to make treatment decisions.    

Reason for Recall  

GE HealthCare is recalling malfunctioning TruSignal sensors that may reduce the amount of energy sent to the heart during defibrillation without any notification to the care provider, which could prevent delivery of lifesaving therapy in a critical situation. This issue is most hazardous to hospitalized patients who may need defibrillation for cardiac arrest. Affected sensors may also unintentionally expose patients to electrical currents from other sources or may provide inaccurate measurements of SpO2, which can impact treatment decisions.  

Use of defective TruSignal SpO2 Sensors may cause serious injuries or death.  

GE HealthCare has received four reported injuries and no reported deaths for this issue.  

Who May be Affected  

  • Adults and children whose SpO2 and pulse rate are continuously monitored using TruSignal SpO2 sensors.  
  • Healthcare providers who use TruSignal SpO2 sensors to monitor adult and pediatric patients.  

What to Do  

On May 19, 2023 GE HealthCare sent affected customers an Urgent Medical Device Correction notice with the following recommended actions: 

  • Use an alternate method for SpO2 monitoring, including TruSignal Sensors not impacted or an alternate SpO2 device. 
  • If alternate methods are not available, use affected TruSignal SpO2 Sensors as long as they have not been saturated with fluids. 
  • Follow the below instructions if defibrillation is necessary when affected TruSignal SpO2 Sensors are being used:  
    • Remove the affected TruSignal SpO2 Sensor 
    • Defibrillate per hospital protocol  
    • Reattach the affected TruSignal SpO2 Sensor after defibrillation is no longer needed  
  • Confirm the Adult/Pediatric SpO2 sensors do not have material covering the emitter or detector before using.  
  • Discard the sensor and use another sensor if any additional material is found to be present. 
  • Make sure all potential users are made aware of this safety notification and the recommended actions, and retain this notice.  
  • Complete and return the acknowledgement form attached to the notice to [email protected].  

Contact Information  

Customers with questions or concerns should contact GE HealthCare Service at 1-800-437-1171 or their local service representative.  

Additional Resources:  

Medical Device Recall Database entry: TruSignal Adult Pediatric Sensor  

Medical Device Recall Database entry: TruSignal AllFit SensorExternal Link Disclaimer  

Medical Device Recall Database entry: TruSignal Sensitive Skin Sensor  

Medical Device Recall Database entry: TruSignal Wrap Sensor 

Medical Device Recall Database entry: TruSignal Ear Sensor  

Medical Device Recall Database entry: TruSignal Integrated Ear Sensor with GE Connector 

Medical Device Recall Database entry: TruSignal Integrated Ear Sensor with Datex Connector  

Medical Device Recall Database entry: TruSignal Integrated Ear Sensor with Datex Connector  

Medical Device Recall Database entry: TruSignal Integrated Ear Sensor with Ohmeda Connector  

How do I report a problem? 

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program using the online form or call 1-800-332-1088 for more information on how to mail or fax the form.


Related Content

News | FDA

April 25, 2024 — Provisio Medical announced FDA 510(k) clearance of the Provisio SLT IVUS System. Sonic Lumen Tomography ...

Home April 25, 2024
Home
News | FDA

April 24, 2024 — Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food ...

Home April 24, 2024
Home
News | FDA

April 22, 2024 — At the annual American College of Cardiology conference (ACC.24) in Atlanta last week, RCE Technologies ...

Home April 22, 2024
Home
News | FDA

April 18, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently ...

Home April 18, 2024
Home
News | FDA

April 15, 2024 — The U.S. Food and Drug Administration (FDA) announced Abbott/Thoratec Corp. is recalling HeartMate II ...

Home April 15, 2024
Home
News | FDA

April 12, 2024 — Simpson Interventions, Inc., a pioneering medical technology company specializing in cardiovascular ...

Home April 12, 2024
Home
News | FDA

April 2, 2024 — Medical device technology developer Concept Medical has announced it has been granted Investigational ...

Home April 02, 2024
Home
News | FDA

April 2, 2024 — Abbott announced that the U.S. Food and Drug Administration (FDA) approved the company's first-of-its ...

Home April 02, 2024
Home
News | FDA

April 1, 2024 — Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new ...

Home April 01, 2024
Home
News | FDA

March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug ...

Home March 28, 2024
Home
Subscribe Now